Abstract
As a leader in the pharmaceutical industry, Pfizer has maintained a long-term leading position in the industry through technology R&D investment and product innovation. Especially in recent years, the drugs and vaccines produced by Pfizer have been widely used worldwide to treat new coronary pneumonia. Pfizer's sales have increased significantly and occupied a significant market share. The rapid accumulation of Pfizer's wealth and the improvement of its operational capabilities have attracted more and more attention from investors. The goal of an enterprise is to obtain profit, and profitability is an essential indicator for evaluating the profit of an enterprise. No matter which stakeholder of the enterprise pays excellent attention to the profitability of the enterprise, standard analysis methods need to convey more information to investors. This article analyzes Pfizer's 2020-2022 financial statements using the DuPont analysis method to find out the problems that Pfizer has in terms of profitability and puts forward some opinions for investors' reference.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
